Wellington Management Group LLP reduced its stake in shares of AtriCure Inc. (NASDAQ:ATRC) by 11.9% during the first quarter, according to its most recent filing with the SEC. The fund owned 2,221,863 shares of the medical device company’s stock after selling 299,159 shares during the period. Wellington Management Group LLP owned approximately 7.25% of AtriCure worth $37,394,000 as of its most recent filing with the SEC.
A number of other large investors also recently made changes to their positions in ATRC. Wells Fargo & Company MN raised its stake in shares of AtriCure by 20.2% in the fourth quarter. Wells Fargo & Company MN now owns 659,070 shares of the medical device company’s stock worth $14,789,000 after buying an additional 110,890 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of AtriCure by 15.3% in the fourth quarter. Victory Capital Management Inc. now owns 51,647 shares of the medical device company’s stock worth $1,159,000 after buying an additional 6,845 shares in the last quarter. Paradigm Capital Management Inc. NY raised its stake in shares of AtriCure by 108.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 247,525 shares of the medical device company’s stock worth $5,554,000 after buying an additional 128,700 shares in the last quarter. RS Investment Management Co. LLC raised its stake in shares of AtriCure by 21.1% in the fourth quarter. RS Investment Management Co. LLC now owns 2,679,551 shares of the medical device company’s stock worth $60,129,000 after buying an additional 466,200 shares in the last quarter. Finally, Cortina Asset Management LLC raised its stake in shares of AtriCure by 5.5% in the fourth quarter. Cortina Asset Management LLC now owns 679,166 shares of the medical device company’s stock worth $15,240,000 after buying an additional 35,478 shares in the last quarter.
Shares of AtriCure Inc. (NASDAQ:ATRC) traded down 0.33% during midday trading on Wednesday, reaching $14.90. The company’s stock had a trading volume of 154,883 shares. The firm’s market capitalization is $493.10 million. The stock has a 50-day moving average of $15.08 and a 200 day moving average of $16.08. AtriCure Inc. has a 12-month low of $13.44 and a 12-month high of $28.15.
A number of equities research analysts have weighed in on ATRC shares. Canaccord Genuity reiterated a “buy” rating on shares of AtriCure in a research note on Tuesday, July 12th. Zacks Investment Research upgraded shares of AtriCure from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Tuesday, May 3rd. Needham & Company LLC reiterated a “buy” rating on shares of AtriCure in a research note on Saturday, April 30th. JMP Securities started coverage on shares of AtriCure in a research note on Thursday, June 30th. They set an “outperform” rating and a $25.00 target price for the company. Finally, Northland Securities started coverage on shares of AtriCure in a research note on Tuesday, March 29th. They set an “outperform” rating and a $24.00 target price for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $24.67.
AtriCure, Inc is a medical device company providing atrial fibrillation (Afib) solutions. The Company’s segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
